Nobel laureate Carolyn Bertozzi returns to the Lilly board
Nobel Prize-winning chemist Carolyn Bertozzi rejoined Eli Lilly's board on December 8, 2025, a move the company says will support its work in cancer and other diseases, including obesity treatments like Zepbound.
Eli Lilly and Company said its board of directors elected Carolyn R. Bertozzi, Ph.D., as a returning member effective December 8, 2025 [1]. Bertozzi previously served on Lilly's board from 2017 to 2021 [1]. She will now sit on the board's Science and Technology committee and its Ethics and Compliance committee [1].
Lilly chair and CEO David A. Ricks welcomed her back, calling her "a Nobel Prize-winning chemist whose work has fundamentally changed how we think about developing targeted medicines, particularly in cancer" [1]. Ricks said her perspective would be valuable as Lilly works "to pioneer new approaches in oncology and immunology" and to "deliver more breakthrough medicines to patients" [1].
According to the company, Bertozzi currently holds several roles at Stanford University: she is the Baker Family director of Sarafan ChEM-H, the Anne T. and Robert M. Bass professor in the School of Humanities and Sciences, and a courtesy professor of Chemical and Systems Biology and of Radiology [1]. She is also an Investigator of the Howard Hughes Medical Institute [1]. Lilly's announcement notes she has been elected to the National Academy of Medicine, the National Academy of Sciences, and the American Academy of Arts and Sciences [1].
The press release does not spell out the specifics of Bertozzi's Nobel Prize, her research focus, or whether any other Lilly director also holds a Nobel Prize. Those details are not confirmed in the available source and are not yet known from this reporting.
Why it matters for patients
This is a corporate governance move, not a drug approval or a change to any product. Lilly makes tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for weight loss, along with insulin products and cancer treatments. Board appointments do not change how these medicines work, their prices, insurance coverage, or safety profiles.
Still, patients who follow Lilly as a company sometimes track its leadership because board members help set the direction for research spending and can influence which disease areas the company prioritizes. Lilly's own statement frames Bertozzi's return as tied to its ambitions in "redefining diabetes care" and "treating obesity and curtailing its most devastating long-term effects," alongside oncology and immunology work [1]. For people currently using or considering GLP-1 medicines from Lilly, this announcement offers a signal about the company's broader research priorities rather than any immediate, tangible change to treatment.
The release also repeats standard cautionary language that Lilly attaches to forward-looking statements, noting risks in the research, manufacturing, and commercialization of its products that could affect outcomes for any of its medicines [1]. That boilerplate applies broadly to Lilly's pipeline and is not specific to any single drug or condition.
What happens next
Lilly's announcement does not include a timeline for specific research outcomes tied to Bertozzi's return, nor does it name additional board changes. The company said it will continue publishing news through its investor relations channels, including references to future events such as a September 2026 healthcare conference appearance listed alongside this release [1]. No further specifics about Bertozzi's committee work or its effect on Lilly's GLP-1 or oncology programs were provided in the source material, so those developments remain to be seen.
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.